Johnson & Johnson (JNJ)vsTG Therapeutics Inc (TGTX)
JNJ
Johnson & Johnson
$269.29
-0.10%
HEALTHCARE · Cap: $640.02B
TGTX
TG Therapeutics Inc
$58.11
+1.66%
HEALTHCARE · Cap: $8.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 12148% more annual revenue ($97.93B vs $799.54M). TGTX leads profitability with a 55.2% profit margin vs 21.5%. TGTX appears more attractively valued with a PEG of 1.61. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
TGTX
Buy56
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Every $100 of equity generates 79 in profit
Keeps 55 of every $100 in revenue as profit
Revenue surging 70.3% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Expensive relative to growth rate
Trading at 14.1x book value
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : TGTX
The strongest argument for TGTX centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 55.2% and operating margin at 9.0%. Revenue growth of 70.3% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, Price/Book, Debt/Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TGTX is a growth play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.66 — expect wider price swings.
TGTX is growing revenue faster at 70.3% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 56/100), backed by strong 21.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?